公开(公告)号：US11999784B2

公开(公告)日：2024-06-04

申请号：US16451051

申请日：2019-06-25

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2803 ,  C07K16/3061 ,  G01N33/57407 ,  C07K2317/73 ,  C07K2317/732 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US11078275B2

公开(公告)日：2021-08-03

申请号：US16240906

申请日：2019-01-07

Applicant: INNATE PHARMA

Inventor： Cecile Bonnafous ,  Helene Sicard ,  Renaud Buffet

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US10344087B2

公开(公告)日：2019-07-09

申请号：US14767600

申请日：2014-02-13

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet ,  Mathieu Blery

IPC: A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US12084498B2

公开(公告)日：2024-09-10

申请号：US17388052

申请日：2021-07-29

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Hélène Sicard ,  Renaud Buffet

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2803 ,  C07K16/3023 ,  C07K16/3061 ,  G01N33/57426 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US10174112B2

公开(公告)日：2019-01-08

申请号：US15623572

申请日：2017-06-15

Applicant: INNATE PHARMA

Inventor： Cecile Bonnafous ,  Helene Sicard ,  Renaud Buffet

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.